Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Early Stage Triple-Negative Breast Carcinoma
Interventions: BIOLOGICAL: Pembrolizumab|OTHER: Patient Observation|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment
Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)